NCT02678000View on ClinicalTrials.gov

Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function

PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

March 10, 2017

Primary Completion Date

October 11, 2018

Study Completion Date

October 11, 2018

Conditions
Chronic Kidney Disease (CKD)
Interventions
DRUG

LHW090

LHW090 is orally administered

DRUG

Placebo

Matching placebo of LHW090

Trial Locations (12)

13353

Novartis Investigative Site, Berlin

22143

Novartis Investigative Site, Hamburg

32810

Novartis Investigative Site, Orlando

33014

Novartis Investigative Site, Miami Lakes

41061

Novartis Investigative Site, Mannheim

55114

Novartis Investigative Site, Saint Paul

55404

Novartis Investigative Site, Minneapolis

70119

Novartis Investigative Site, New Orleans

80228

Novartis Investigative Site, Lakewood

91054

Novartis Investigative Site, Erlangen

92801

Novartis Investigative Site, Anaheim

04910

Novartis Investigative Site, Elsterwerda

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY